Dupilumab Under Review for Atopic Dermatitis in Children Aged 5 Years and Younger
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.
Diagnosis & Disease Information
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
Dermatology in Skin of Color: From Unmet Needs to Culturally Competent Care
Disparities in dermatology and the role of ethnic skin centers in addressing these issues are discussed with Angela Lamb, MD.
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Atopic Dermatitis Associated With Shorter Height, Increased BMI in Early Childhood
The largest longitudinal study to date explores the relationship between childhood atopic dermatitis (AD) and height and BMI.
Trial Evaluating Lebrikizumab Plus TCS in Atopic Dermatitis Meets Endpoints
The ADhere trial evaluated lebrikizumab in combination with topical corticosteroids in adults and adolescents with moderate to severe atopic dermatitis.
Hair Loss in Women is More Than a Cosmetic Concern
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
FDA Grants Fast Track Designation to Orismilast for Atopic Dermatitis
The FDA’s Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
Worsening of Atopic Dermatitis During Pregnancy Uncommon
The prevalence and predictors of patient-reported worsening of AD symptoms during pregnancy are examined.
Oral and Topical Antifungals Beneficial for Dupilumab Facial Redness in Atopic Dermatitis
A novel study reports the positive response to oral and topical antifungals for patients with atopic dermatitis (AD) treated with dupilumab who developed facial redness.
- Loading...
Loading...
Next post in News
Loading... 
Loading...